AstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth

Astrazeneca Pharma India's share price jumped over 10% after the company reported strong fourth-quarter results, showcasing growth across key financial metrics. The pharmaceutical giant's revenue for the quarter increased by 25.3% year-on-year, reaching Rs 480 crore compared to Rs 383 crore in the same period last year.

The company's earnings before interest, taxes, depreciation, and amortisation saw a rise of 74.4%, amounting to Rs 85.8 crore versus Rs 49.2 crore previously. This improvement was reflected in the Ebitda margin, which expanded to 17.9% from 12.8%.

Net profit also grew by 47.5% to Rs 58.3 crore from Rs 39.5 crore.

AstraZeneca Pharma India is a subsidiary of AstraZeneca PLC, a global biopharmaceutical company. It focuses on the development, manufacturing, and marketing of pharmaceutical products in India.

The company is known for its medicines in areas such as oncology, cardiovascular, renal, and metabolic diseases. AstraZeneca Pharma India leverages its parent company's extensive research and development capabilities to bring treatments to the Indian market.

The scrip rose as much as 10.70% to Rs 8,825 apiece. It pared some gains to trade 10.27% higher at Rs 8,790 apiece, as of 10:21 a.m. This compares to a 0.77% decline in the NSE Nifty 50.

It has risen 44.89% in the last 12 months. Total traded volume so far in the day stood at 66 times its 30-day average. The relative strength index was at 67.